亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

p53abn Endometrial Cancer: understanding the most aggressive endometrial cancers in the era of molecular classification

子宫内膜癌 医学 浆液性液体 肿瘤科 内科学 癌症 癌症研究
作者
Amy Jamieson,Emily F. Thompson,Jutta Huvila,C. Blake Gilks,Jessica N. McAlpine
出处
期刊:International Journal of Gynecological Cancer [BMJ]
卷期号:31 (6): 907-913 被引量:65
标识
DOI:10.1136/ijgc-2020-002256
摘要

Over the past decade, our understanding of endometrial cancer has changed dramatically from the two-tiered clinicopathologic classification system of type I and type II endometrial cancer through to the four distinct molecular subtypes identified by The Cancer Genome Atlas (TCGA) in 2013. In both systems there is a small subset of endometrial cancers (serous histotype/high numbers of somatic copy number abnormalities) that account for a disproportionately high percentage of endometrial cancer related deaths. This subset can be identified in routine clinical practice by first identifying the approximately one-third of endometrial cancers that are either ultramutated/ POLE mut tumors, with pathogenic mutations in the exonuclease domain of POLE , or hypermutated/MMRd tumors, with loss of DNA mismatch repair. Immunostaining for p53 stratifies the remaining endometrial cancers into those with wild-type staining pattern and those with mutant pattern staining (p53abn endometrial cancer). This latter group of p53abn endometrial cancer is the subject of this review. Most p53abn endometrial cancers are serous type and high grade, but it also includes other histotypes and lower grade tumors, and has consistently been associated with the poorest clinical outcomes. Although it only accounts for 15% of all endometrial cancer cases, it is responsible for 50–70% of endometrial cancer mortality. A better understanding of the molecular alterations in the p53abn subgroup, beyond the ubiquitous and definitional TP53 mutations, is required so we can identify better treatments for these most aggressive endometrial cancers. Recent evidence has shown improved survival outcomes with the addition of chemotherapy compared with radiation alone in p53abn endometrial cancers. Opportunities for targeted therapy for p53abn endometrial cancers also exist with a proportion of p53abn endometrial cancers known to have homologous recombination deficiency (HRD) or human epidermal growth factor 2 (HER2) overexpression/amplification. This review will provide an overview of our current understanding of p53abn endometrial cancer.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
在水一方应助阿九采纳,获得10
1秒前
1秒前
ZT完成签到,获得积分10
5秒前
搜集达人应助zhouleiwang采纳,获得10
6秒前
吴嘉俊发布了新的文献求助10
7秒前
仙人掌王朝完成签到,获得积分10
9秒前
12秒前
Hello应助zhouleiwang采纳,获得10
12秒前
阿九完成签到,获得积分10
15秒前
lllxxx完成签到 ,获得积分10
16秒前
lv发布了新的文献求助10
17秒前
冉亦完成签到,获得积分10
21秒前
WGS完成签到,获得积分10
22秒前
科研通AI2S应助科研通管家采纳,获得10
23秒前
华仔应助科研通管家采纳,获得20
23秒前
吉吉吉完成签到 ,获得积分10
25秒前
26秒前
阿九发布了新的文献求助10
31秒前
大胆的小懒猪完成签到 ,获得积分10
33秒前
111完成签到 ,获得积分10
34秒前
36秒前
yx_cheng应助001az采纳,获得30
36秒前
37秒前
miles完成签到,获得积分10
40秒前
简单山水发布了新的文献求助10
43秒前
Yina完成签到 ,获得积分10
1分钟前
友好胜完成签到 ,获得积分10
1分钟前
田様应助滴滴哒采纳,获得10
1分钟前
苔原猫咪甜甜圈完成签到,获得积分10
1分钟前
研友_ngkyGn应助Long采纳,获得10
1分钟前
LJ_scholar完成签到,获得积分10
1分钟前
斯文败类应助Ansaista采纳,获得10
1分钟前
善学以致用应助简单山水采纳,获得10
1分钟前
1分钟前
淡定的思松完成签到 ,获得积分10
1分钟前
滴滴哒发布了新的文献求助10
1分钟前
1分钟前
月亮完成签到 ,获得积分10
1分钟前
爹爹完成签到,获得积分10
1分钟前
爹爹发布了新的文献求助10
1分钟前
高分求助中
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3990012
求助须知:如何正确求助?哪些是违规求助? 3532049
关于积分的说明 11256153
捐赠科研通 3270925
什么是DOI,文献DOI怎么找? 1805123
邀请新用户注册赠送积分活动 882270
科研通“疑难数据库(出版商)”最低求助积分说明 809216